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Abstract
Purpose: Oxidative stress plays a pivotal role in the pathogenesis of the metabolic syn-
drome and in the progression of its complications. Carbonylated proteins are a stable 
marker of severe oxidative  stress because damage to the protein structure is irreversible and 
may cause an inhibition of their enzymatic activity or an increased susceptibility to prote-
olysis. ere are few data regarding protein oxidation in metabolic syndrome, although 
elevated levels of carbonyl groups are oen detected in subjects with obesity, diabetes mel-
litus, hypertension or dyslipidemia, well-known components of the metaboic syndrome. In 
particular, obesity, insulin resistance and diabetes mellitus are frequently associated with 
increased protein carbonylation. A relationship between insulin resistance, protein oxida-
tive stress and inammation has also been suggested as well as protein oxidation products 
are correlated with overexpression of resistin, TNF-α and IL-6. 
Conclusion: erapeutic interventions based on lifestyle modications and pharmacol-
ogical agents in order to correct all the main risk factors inuence oxidative stress and pro-
tein carbonylation.
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Metabolic syndrome (MS) is characterized by a high risk of 
cardiovascular morbidity and mortality [1,2].  e compo-
nents that dene MS, such as visceral obesity, hypertension, 
diabetes mellitus and dyslipidemia, all show both the altered 
oxidant/antioxidant status and chronic subclinical inamma-
tion that are responsible for accelerated atherosclerosis.
Previously, oxidative stress has been shown to play a role in 
MS development [3]. Several components of this syndrome, 
including hyperglycemia and inammation, induce an in-
creased production of reactive oxygen species (ROS) [4]. ROS 
and reactive nitrogen species (RNS) are also involved in aging, 
neurodegenerative diseases and other clinical conditions. e 
main ROS is the superoxide anion (O2-), which is rapidly neu-
tralized by anti-oxidant enzymes in vivo, and, in the case of 
endothelial dysfunction, oxidizes nitric oxide (NO), producing 
peroxinitrite and starting a cascade of ROS generation that 
leads to the oxidation of carbohydrates, lipids and proteins [3].
Oxidative stress is oen caused by hyperactivity of 
NADPH oxidase with a consequent synthesis of ROS and a 
reduced bioavailability of NO [5]. NO levels are decreased in 
subjects with metabolic diseases and are negatively correlated 
with body mass index (BMI), blood pressure and triglyceride-
mia [6]. Activated phagocytes are another source of ROS: neu-
trophils contain myeloperoxidase (MPO), which catalyzes the 
reaction between chloride ion and hydrogen peroxide to gener-
ate hypochlorous acid. Hypochlorous acid oxidizes proteins, 
especially albumin, producing advanced oxidation protein 
products (AOPPs) [7].
Proteins are the principal target of ROS and RNS because 
they are present in high concentrations in biological systems 
and remove 50-75% of the generated ROS [7]. AOPPs are 
formed mainly as a consequence of the action of chlorinated 
compounds, leading to the production of dityrosine residues 
and to protein crosslinking [7]. AOPP may play a part in the 
expansion and preservation of both oxidative stress and in-
ammation by the activation of neutrophils, monocytes and T 
lymphocytes [8]. In vitro, AOPPs are able to inhibit inducible 
NO production by macrophages [9] and to induce ROS pro-
duction in endothelial cells via NADPH oxidase activation 
[10].
ROS and RNS may modify protein structure directly or 
indirectly [11]. ROS- and RNS-induced lipid peroxidation 
generates some relatively stable end products, such as malondi-
aldehyde (MDA), hydroxynonenal (HNE), oxononenal 
(ONE) and isoprostanes [11]. Aminoacid modication by α/β-
unsaturated aldehydes oen occurs at the nucleophilic residues 
of cysteine, histidine and lysine.  e damage of the protein 
may cause the cleavage of the primary structure, cross-linking 
or modications of a single amino acid chain [11]. 
Oxidation of the thiol groups of cysteine residues by ROS 
and RNS can signicantly modify the structure and function 
of proteins. By reacting with ROS and RNS, thiol groups func-
tion as antioxidants. Some of the ROS- and RNS-induced 
modications of cysteine residues are reversible, including glu-
tathionylation, sulfenic acid formation, S-nitrosylation, S-
acylation, sulfanilamide production and disulde formation, 
while some reactions with ROS and RNS produce irreversible 
products such as sulnic or sulfonic acids and thioethers 
[12,13]. ese protein changes may either be biomarkers of 
oxidative damage or may defend against oxidative stress.
Carbonylation is an irreversible ROS-induced protein 
modication. ere are many ways to introduce carbonyl 
groups into a protein structure: ROS may directly oxidize ly-
sine, arginine, proline or threonine residues, or may react with 
carbohydrates and lipids generating reactive carbonyl species 
(RCS), such as ketoamine, ketoaldehydes, MDA, HNE and 
ONE, which subsequently interact with proteins [14]. HNE 
and ONE may react with nucleophilic amino acids producing 
Michael and Schi adducts that are then modied by tauto-
merization, oxidation, dehydration and sometimes condensa-
tion with another aldehyde to generate stable advanced lipoxi-
dation end products (ALEs) [15]. e damage to the protein 
structure is generally irreversible and may cause inhibition of 
enzymatic activity, increased susceptibility to aggregation and 
proteolysis and altered cellular uptake [11]. 
Oxidized proteins ares usually catabolized by proteasomes 
and lysosomes, but some inactive proteins may be poorly de-
graded, generating protein aggregates that accumulate inside 
the cells or in the extracellular matrix [11]. 
In the literature, there are two papers regarding protein 
oxidation or carbonylation in MS subjects. In the rst, [16] the 
behavior of protein oxidation, expressed as AOPPs/albumin 
ratio, has been examined in relation to a number of risk factors 
in MS subjects subdivided in omnivores and vegetarians. is 
AOPPs/albumin ratio, which is higher in the vegetarian group, 
was correlated with the following risk factors: BMI, blood 
pressure, glucose metabolism and lipid pattern. In the second 
paper, [17] protein oxidation, expressed as AOPPs and car-
bonyl groups, was investigated in 60 subjects with MS subdi-
vided according to the presence or absence of metformin 
treatment; this study showed a signicant decrease in AOPPs 
(49%) and in carbonyl groups (51%)  only in the group treated 
with metformin (850 mg once daily for 1 year).
Even if there are only limited data on protein oxidation in 
subjects with MS, there is more evidence of these protein 
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changes in subjects with visceral obesity, diabetes mellitus, arte-
rial hypertension and dyslipidemia; principal components of 
MS.
Obesity
In obese subjects, elevated AOPP levels were correlated with 
central obesity, triglyceridemia, lipid peroxidation and insu-
linemia, and are reduced by weight loss [18]. In a small group 
of obese subjects, Frohnert and coworkers [19] demonstrated 
higher concentrations of carbonylated proteins in subcutane-
ous adipose tissue, which positively correlated with adiposity 
and plasma levels of free fatty acids. In another study, [20] 
obese women showed increased plasma AOPP in comparison 
with lean controls.  ese AOPP levels were more elevated in 
those with diabetes mellitus and were related to higher concen-
trations of resistin, TNF-α and IL-6. Zhou et al. [21] demon-
strated that the exposure of the adipocytes to levels of AOPPs, 
comparable to serum concentrations found in subjects with 
obesity and diabetes mellitus, induced a cellular alteration and 
an overexpression of TNF-α and IL-6 in a dose- and time-
dependent manner, probably via NF-kB activation. is study 
underlines a correlation between insulin resistance, oxidative 
stress and inammation. Atabek and coworkers [22] observed 
higher values of AOPP in obese adolescents with insulin resis-
tance relative to lean controls, although the dierence was not 
statistically signicant.
Other authors have demonstrated a positive correlation 
between carbonylated proteins, HOMA index and BMI in 
obese subjects and also a decrease of these proteins aer gastric 
banding [23]. Obese subjects who underwent bariatric surgery 
show a weight loss accompanied by the improvement of meta-
bolic parameters and a decrease of carbonyl groups [24]. Even 
weight loss obtained with caloric restriction and physical activ-
ity was associated with a decrease in some parameters of oxida-
tive stress, such as thiobarbituric acid-reactive substances 
(TBARS), nitrotyrosines and carbonylated proteins [25]. In 
obese children, following low-calorie diet, the consumption of 
mandarin juice, rich in antioxidants, contributed to a decrease 
in carbonyl groups and MDA [26].  In obese subjects with MS, 
metformin administration (for one year) reduced body weight, 
abdominal circumference and oxidative/nitrosative stress pa-
rameters and improved NO concentration and endothelial 
function [16]. 
Elevated levels of protein oxidation have been demon-
strated in response to obesity, and are correlated with the pres-
ence of adipose tissue, insulin resistance and inammation. 
Furthermore, protein oxidation may be reduced by lifestyle 
modications and pharmacological therapy directed towards 
weight loss.
Diabetes mellitus
Hyperglycemia may contribute to the plasma and cellular pro-
tein damage mediated by oxidation and glycation. Protein gly-
cation produces advanced glycation end products (AGEs) and 
is oen mediated by alpha-dicarbonyls (glyoxal and meth-
ylglyoxal), produced by protein glycation (non-oxidative reac-
tion) or by lipid peroxidation (markers of oxidative stress). 
In diabetes, an increment in the polyol or sorbital path-
ways may cause an altered NADH/NAD+ ratio and 
NADPH/NADP+ ratio, respectively, aecting the detoxica-
tion process [27,28]. ese alterations, together with an ele-
vated concentration of carbohydrate and lipid compounds, 
may produce higher levels of RCS [27,28].  is condition can 
be considered to be determined by carbonyl stress and not by 
oxidative processes, so some authors retain that it is possible to 
distinguish oxidative stress from carbonyl stress, especially in 
diabetes mellitus.
In diabetes, elevated concentrations of asymmetric di-
methyl arginine (ADMA) and low levels of tetrahydrobiop-
terin (BH4) may lead to an impaired NOS regulation [29,30]. 
BH4 binds the oxidase domain of NO synthase (NOS) and it 
is an essential co-factor for the synthesis of NO while as it is 
known ADMA is an inhibitor of NOS [31].
Methionine sulfoxide and N’-formylkynurenine, which are 
derived from oxidation of methionine and tryptophan, are 
markers of protein oxidative damage [32]. Some authors [32] 
found a decrease in plasma levels of glycation products and of 
carboxyl-metil-lysine derived from glyoxal in patients treated 
with insulin to decrease post-prandial hyperglycemia. 
Telci and coworkers reported an increase in plasma car-
bonyl levels in type 2 diabetic subjects without chronic com-
plications [33], while others found an increase in protein car-
bonyl concentration in diabetic subjects with and without mi-
croangiopathy as compared with normal subjects [34]. In con-
trast, Odetti et al. demonstrated that the plasma protein car-
bonyl content in type 2 diabetic subjects was slightly but not 
signicantly higher in comparison with normal subjects [35]. 
In the same group of type 2 diabetic subjects was also observed 
a correlation between HbA1c and protein carbonyl 
groups [35]; insulin resistance, expressed as HOMA index, was 
also correlated with higher carbonyl group levels [36].
In rst-degree relatives of type 2 diabetic subjects, in-
creased plasma protein carbonyl content has been de-
scribed  [37]. AOPP, carbonylated proteins and lipoperoxides 
levels were increased in subjects with poorly controlled diabe-
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tes mellitus [38]. eir levels were elevated in most type 2 dia-
betic subjects, positively correlated with triglyceridemia [39] 
and higher in those with cardiovascular complications [40,41]. 
AOPP, carbonyl groups and thiol-proteins levels were in-
creased in plasma and urine of type 2 diabetic subjects with 
nephropathy and the AOPP values were associated with albu-
minuria and kidney disease progression [42]. In women with 
gestational diabetes, an increased concentration of protein oxi-
dation markers, such as AOPP, protein carbonyls, protein hy-
droperoxides and nitrotyrosine, was found [43]. is nding 
was associated with a reduced activity of paraoxonase-1, a 
peroxidase-like enzyme that defends against lipoprotein oxida-
tion [43]. AOPPs are also involved in diabetic retinopathy de-
velopment [44]. 
Increased protein carbonylation has been demonstrated in 
erythrocyte membrane of diabetic subjects, especially in sub-
jects with proliferative retinopathy [45,47]. e presence of 
diabetic foot ulcers is also associated with higher plasma MDA 
and carbonyl levels, and these parameters were correlated with 
worsened outcomes [48]. 
A three-fold higher concentration of residues modied by 
glycation, oxidation and nitrosylation in plasma proteins and a 
two-fold higher concentration in hemoglobin was noted in 
type 1 diabetic subjects in comparison with normal sub-
jects [49]. 
ese observation are comparable with those of Dom-
inguez and coworkers [50]who found that the plasma carbonyl 
groups were signicantly higher in diabetic children and ado-
lescents in comparison with normal subjects.
In streptozotocin-induced diabetic rats, the administration 
of antioxidants, such as stobadine, reduced plasma levels of 
sulydrylic groups and thiol-proteins and liver concentrations 
of carbonylated proteins and AOPP, but not of N-tyrosine 
(51); as expected, stobadine did not improve glycometabolic 
control. In animal models, glomerular stores of AOPP cause 
podocyte apoptosis via activation of NADPH oxidase and cas-
pases, thus promoting glomerulosclerosis (52). 
In rats, aer 8 weeks of the induction of diabetes, carbony-
lation of ventricular myosin heavy chains was observed, dem-
onstrating that heart modications induced by RCS may lead 
to diabetic cardiomyopathy (53).
Protein alterations in diabetes mellitus can be observed 
early in the course of disease and are correlated with glycemic 
control and vascular complications; administration of insulin 
reduces intermediates of oxidative and carbonyl stress involved 
in the generation of RCS.
Hypertension
NADPH oxidase activation, due to stimulation of AT1 recep-
tors, may be responsible for an increase in the production of 
ROS and a consequent decrease in NO availability in response 
to arterial hypertension [3].  In addition, ADMA is increased 
in hypertension, causing a decrease in vascular compliance and 
elevated sodium retention [31].
A prospective study [54] showed that elevated RCS levels 
are associated with the development of pre-hypertension and 
hypertension, and that RCS and blood pressure values are sig-
nicantly correlated. is study seems to suggest how protein 
oxidation is involved in hypertension progression. Some 
authors have proposed a possible role of RCS and oxidized 
thiol-proteins in the pathogenesis and in the maintenance of 
renovascular hypertension [55-57]. In contrast, others consider 
oxidative stress as a consequence of hypertension, due to the 
altered activity of enzymatic antioxidants [58]. ese same 
authors found greater protein oxidative damage at all stages of 
hypertension and a positive correlation between blood pressure 
values and oxidative stress parameters. In subjects in the initial 
stage of essential hypertension, an increase in plasma carbony-
lated protein, associated with a decrease of antioxidant de-
fences, in particular the reduced glutathione, was noted[59]. 
Even in subjects with sustained hypertension and white coat 
hypertension, increased levels of carbonylated proteins were 
observed, and no signicant dierences were observed between 
the two groups of hypertensives [60]. Caimi and coworkers 
did not nd any dierence in carbonyl groups between un-
treated subjects with mild essential hypertension and normal 
subjects [61]. Anti-hypertensive treatment with perindopril 
(an ACE inhibitor) and hydroclorothiazide for 45 days re-
duced carbonylated proteins and increased the activity of su-
peroxide dismutase and catalase and the NO concentrations in 
elderly hypertensive subjects [62]. 
In spontaneously hypertensive rats, an increase in carbony-
lated proteins has been described in myocardial tissue [63], 
where it is associated with higher caspase activity, as well as in 
the kidney and aorta [64].  
Pharmacological control of arterial hypertension may, 
therefore, attenuate the oxidative damage and delay the pro-
gression of cardiovascular complications.
Dyslipidemia
Hyperlipidemia is associated with oxidative stress and inam-
mation. In hypercholesterolemic subjects, a correlation be-
tween total cholesterol and protein carbonyl levels was found, 
as well as a dierence in carbonyl groups between subjects with 
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total cholesterol varyng from 200 to 240 mg/dl and those with 
total cholesterol above 240 mg/dl [65]. Hypercholesterolemic 
subjects showed an increase in TBARS and carbonylated pro-
teins, especially if subjects had a superoxide dismutase genetic 
polymorphism (Ala16Val) [66]. e subjects with homozy-
gous familial hypercholesterolemia have higher levels of MDA 
and carbonylated proteins than subjects with heterozygous 
familial hypercholesterolemia, which correlated with LDL-C 
and Lpa levels, intima-media thickness and with increased car-
diovascular risk [67]. AOPP concentration was positively cor-
related with triglyceridemia in a heterogeneous group of hospi-
talised patients [68]. In diabetic dyslipidemic subjects, the 
treatment with statins decreased carbonyl groups and MDA 
levels [69] and thiol groups were correlated inversely with 
apolipoprotein B and positively with apolipoprotein A-I.
In animal models of hyperlipidemia, increased ROS gen-
eration and over-expression of the NADPH oxidase gp91phox 
subunit in granulocytes have been observed [70]. Hypercholes-
terolemic rabbits had higher NADPH oxidase activity in their 
aorta, with stores of nitrotyrosine in the endothelium and in-
tima and reduced eNOS and SOD activity [71]. In dyslipi-
demic rats following a  hypercaloric diet, an increase in MDA, 
nitrotyrosine and carbonylated proteins was noted and these 
parameters decreased with the administration of eicosapen-
taenoate-lipoate (EPA-LA) derivative [72]. In dyslipidemic 
rabbits, administration of atorvastatin reduced protein oxida-
tion [73].
An increase in protein oxidation is associated with dyslipi-
demia; thus, the use of drugs that decrease lipid levels may re-
duce oxidative stress and attenuate the development of vascular 
lesions.
Conclusions
Protein carbonylation is an indicator of oxidative protein dam-
age.  Its use as a biomarker of oxidative stress has some advan-
tages because of the early synthesis and the stability of carbony-
lated proteins in comparison with other oxidation products. 
Protein structure is irreparably compromised by carbonylation, 
which may occur via dierent ways: direct oxidation of lysine, 
arginine, proline and threonine residues, or interaction with 
RCS produced from carbohydrate and lipid oxidation and by 
non-oxidative reactions with dicarbonyl compounds. Increased 
levels of protein oxidation products may be observed in obe-
sity, diabetes, hypertension and dyslipidemia, principal com-
ponents of MS, suggesting that the presence of carbonyl groups 
in proteins may be considered as important markers of oxida-
tive stress in this syndrome (Table 1). Diet and physical activ-
ity, besides inducing weight loss and exerting the well-known 
eects on metabolic control, blood pressure and lipid prole, 
reduce the parameters of lipid and protein oxidation, so life-
style modications are useful to normalize oxidative status too. 
Interestingly, some drugs commonly employed in the treatment 
of MS, such as metformin and insulin for the treatment of dia-
betes, perindopril and hydrochlorothiazide for hypertension 
and statins for dyslipidemia, have antioxidant eects. Regard-
ing the eects of antioxidant supplementation on cardiovascu-
lar outcomes, data in the literature are conicting:, while in 
vitro and in vivo studies have demonstrated promising antia-
therogenic and cardioprotective eects of vitamin C and E, 
metallothionein, resveratrol and glutathione peroxidase ana-
logues [74,75], several clinical trials, in which patients were 
given antioxidant vitamins, showed no benet [76-80]. One 
explanation for those negative ndings may be the concomi-
tant use of other drugs, such as statins or antiplatelets, com-
monly prescribed to patients with high cardiovascular risk. 
Statins could inuence oxidative status and then abolish the 
potential benecial eect of vitamins, while antiplatelet drugs, 
such as aspirin and clopidogrel, may interfere with the activity 
of antioxidants [81]. Some authors instead suggest that a com-
plex supplementation with vitamins B, C, D, E, K, N-
acetylcysteine, allopurinol, co-enzyme Q and alpha-lipoic acid 
associated with a diet rich in avonoids and carotenoids may 
be necessary in order to obtain eective antioxidant prevention 
and protection against cardiovascular disease [82]. 
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